Ho C H, Yuan C C, Liu S M
Division of Hematology, Veterans General Hospital, Taipei, Taiwan, Republic of China.
Gynecol Oncol. 1999 Dec;75(3):397-400. doi: 10.1006/gyno.1999.5610.
The aim of this study was to find out whether any of the fibrinolytic parameters could be used as tumor markers in predicting the prognosis of ovarian cancers.
In the present study, we determined the plasma concentrations of tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), PAI-2, and uPA receptor (uPAR) in 25 patients with ovarian cancer, 16 patients with benign gynecologic tumor or inflammation, and 36 healthy controls in order to find out whether the plasma levels of these markers could be used to evaluate the prognostic value in patients with gynecologic cancers. We also determined two tissue concentrations of malignant tumor (one was at the tumor site itself and the other at the cut-end tissue of the tumor, which was expected to be free of tumor) in order to see the correlation between plasma and tissue concentrations.
Plasma PAI-1 was significantly higher in patients with malignancy than in the healthy controls (P = 0.0001). There was no significant correlation between plasma and tissue concentrations, either tumor tissue or cut-end tissue, of the same parameters. Tissue concentrations of uPA, PAI-1, and PAI-2 were significantly higher and tPA significantly lower in the malignant tumor tissue than in the cut-end tissue in the patients with ovarian cancer (P = 0.014, 0.03, 0.002, and 0.01, respectively). Plasma PAI-1 was significantly higher in patients in the late stage of ovarian cancer than in the early stages and in the controls.
From our study, we concluded that plasma levels of PAI-1 were correlated with the presence of malignant ovarian cancer and higher stage of disease.
本研究旨在探究是否有任何纤维蛋白溶解参数可作为肿瘤标志物用于预测卵巢癌的预后。
在本研究中，我们测定了25例卵巢癌患者、16例良性妇科肿瘤或炎症患者以及36例健康对照者血浆中组织型纤溶酶原激活物（tPA）、尿激酶型纤溶酶原激活物（uPA）、纤溶酶原激活物抑制剂-1（PAI-1）、PAI-2和uPA受体（uPAR）的浓度，以确定这些标志物的血浆水平是否可用于评估妇科癌症患者的预后价值。我们还测定了恶性肿瘤的两个组织浓度（一个在肿瘤部位本身，另一个在预计无肿瘤的肿瘤切端组织），以观察血浆和组织浓度之间的相关性。
恶性肿瘤患者的血浆PAI-1显著高于健康对照者（P = 0.0001）。相同参数的血浆和组织浓度之间，无论是肿瘤组织还是切端组织，均无显著相关性。卵巢癌患者恶性肿瘤组织中uPA、PAI-1和PAI-2的组织浓度显著高于切端组织，而tPA显著低于切端组织（P分别为0.014、0.03、0.002和0.01）。卵巢癌晚期患者的血浆PAI-1显著高于早期患者和对照组。
从我们的研究中，我们得出结论，血浆PAI-1水平与恶性卵巢癌的存在和疾病的更高分期相关。
